FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981690536> ?p ?o ?g. }

• W1981690536 endingPage "922" @default.
• W1981690536 startingPage "921" @default.
• W1981690536 abstract "Anemia continues to be a major problem in kidney transplant recipients, being mainly related to iron deficiency, gastrointestinal blood loss, and toxicity of immunosuppressants or other pharmacologic agents, such as inhibitors of the renin-angiotensin system (1–3). Here, we report a serious drug-to-drug interaction between mycophenolate mofetil (MMF) and rosiglitazone (4). A 47-year-old male patient received his first cadaveric renal allograft in January 1998. He rapidly recovered renal function (serum creatinine 1.30 mg/dL on day 15 after transplant), and no episodes of acute graft rejection occurred in the early posttransplant period. The patient was on maintenance immunosuppression with cyclosporine A (given at 275 mg daily and kept constant during all the observational period) and MMF (5). Nifedipine and furosemide were started early after transplantation to control high blood pressure. He also received sodium bicarbonate and allopurinol to control hyperuricemia and calcitriol to treat elevated Ca/P. On March 2006, a progressive decline of red blood cell (RBC) count was documented. Erythropoietin therapy was started and anemia partially recovered. On January 2007 the patient was enrolled in a pilot study aimed at evaluating the metabolic and renal effects of rosiglitazone in proteinuric renal transplant recipients. At baseline evaluation serum creatinine concentration and urinary protein excretion were 1.81 mg/dL and 2.06 g per 24 hr, respectively. At this time point mycophenolic acid (MPA) pharmacokinetic measurement was also performed after the morning oral dose of MMF (1,000 mg every 12 hr). The dose-normalized MPA area under the curve (AUC) was 92.2 mg·hr/L/g MMF. Previous reports have shown that MMF exerts a negative effect on erythropoiesis, and that hemoglobin concentrations correlated negatively with MPA plasma levels (6). According to these observations, the daily MMF dose was halved (from 1,000 to 500 mg twice per day). Thereafter, the patient started rosiglitazone therapy (4 mg/day). A week later, ramipril was also introduced to optimize blood pressure control, as requested by the study protocol. After beginning rosiglitazone, a progressive decline in RBC count was shown reaching a nadir value of 3.3 × 106 cells/μL 3 months later, despite the appropriate erythropoietin treatment. Hemoglobin (10.5 g/dL) and hematocrit (31%) were also reduced as compared with baseline. Anemia was not caused by gastrointestinal blood loss, iron deficiency, or hemolysis (lactate dehydrogenase 307 mg/dL and total bilirubin 0.52 mg/dL), and was characterized by erythrocytes with normal mean corpuscular volume (92.8 fL) and mean corpuscular hemoglobin concentrations (34.1 g/dL). At this time, the MPA AUC was twofold higher (194 mg·hr/L/g MMF) than the value measured at baseline visit. Rosiglitazone was discontinued, and progressive increase in RBC count was observed thereafter (Fig. 1). In parallel, hemoglobin (12.2 g/dL) and hematocrit (37%) increased. A third MPA pharmacokinetic evaluation, performed 2 months after rosiglitazone withdrawal, documented a marked reduction in the MPA AUC (131 mg·hr/L/g MMF).FIGURE 1.: Profiles of mycophenolic acid area under the curve and red blood cell count before, during, and after rosiglitazone administration. Time course and dosing of immunosuppressants and other drugs are also reported.Anemia has been reported as a rare event in patients treated with rosiglitazone (7, 8), and thought to be related to the drug-induced plasma volume expansion without effect on erythropoiesis (9). However, in our patient serum sodium concentration did not change significantly during rosiglitazone treatment (serum Na: before, 135.6 mEq/L; during 136.2 mEq/L; recovery 137.4 mEq/L) and body weight had not increased, which argues against a major direct effect of the drug on the RBC count. Instead, we thought that rosiglitazone- associated anemia was caused by interaction of rosiglitazone with MMF metabolism, which eventually translated to suppression of erythropoiesis. This possibility is supported by the significant reduction in the MPA AUC observed after rosiglitazone discontinuation, which paralleled a partial resolution of the anemia, suggesting a potential novel drug-to-drug interaction between MMF and rosiglitazone. The nature of this interaction is unknown. Because both drugs share, at least in part, the same metabolic fate (7, 10), preferential metabolism of rosiglitazone may have taken place, ultimately resulting in less MPA metabolism and eventually high exposure of the patient to the drug. In conclusion, we have first reported a clinically relevant drug interaction between rosiglitazone and MMF, which results in very high MPA plasma concentrations and severe anemia. It is, therefore, advisable to apply strict MPA monitoring with rapid drug dose adjustments when rosiglitazone is given to patients receiving MMF as part of their immunosuppressive therapy. Dario Cattaneo Alessandra Bitto Sara Baldelli Monica Cortinovis Department of Medicine and Transplantation Azienda Ospedaliera Ospedali Riuniti Bergamo and Mario Negri Institute for Pharmacological Research Bergamo, Italy Center for Research on Organ Transplantation “Chiara Cucchi De Alessandri & Gilberto Crespi” Azienda Ospedaliera Ospedali Riuniti Bergamo and Mario Negri Institute for Pharmacological Research Bergamo, Italy Eliana Gotti Department of Medicine and Transplantation Azienda Ospedaliera Ospedali Riuniti Bergamo and Mario Negri Institute for Pharmacological Research Bergamo, Italy Norberto Perico Giuseppe Remuzzi Department of Medicine and Transplantation Azienda Ospedaliera Ospedali Riuniti Bergamo and Mario Negri Institute for Pharmacological Research Bergamo, Italy Center for Research on Organ Transplantation “Chiara Cucchi De Alessandri & Gilberto Crespi” Azienda Ospedaliera Ospedali Riuniti Bergamo and Mario Negri Institute for Pharmacological Research Bergamo, Italy" @default.
• W1981690536 created "2016-06-24" @default.
• W1981690536 creator A5014523351 @default.
• W1981690536 creator A5023556434 @default.
• W1981690536 creator A5031355003 @default.
• W1981690536 creator A5052280892 @default.
• W1981690536 creator A5063740495 @default.
• W1981690536 creator A5083798648 @default.
• W1981690536 creator A5086044070 @default.
• W1981690536 date "2008-03-27" @default.
• W1981690536 modified "2023-09-27" @default.
• W1981690536 title "Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report" @default.
• W1981690536 cites W1994502792 @default.
• W1981690536 cites W2036523293 @default.
• W1981690536 cites W2044068240 @default.
• W1981690536 cites W2076356611 @default.
• W1981690536 cites W2111938066 @default.
• W1981690536 cites W2114713066 @default.
• W1981690536 cites W2138873539 @default.
• W1981690536 cites W2151606421 @default.
• W1981690536 cites W4240449862 @default.
• W1981690536 doi "https://doi.org/10.1097/tp.0b013e318166a210" @default.
• W1981690536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18360279" @default.
• W1981690536 hasPublicationYear "2008" @default.
• W1981690536 type Work @default.
• W1981690536 sameAs 1981690536 @default.
• W1981690536 citedByCount "9" @default.
• W1981690536 countsByYear W19816905362015 @default.
• W1981690536 countsByYear W19816905362017 @default.
• W1981690536 countsByYear W19816905362022 @default.
• W1981690536 crossrefType "journal-article" @default.
• W1981690536 hasAuthorship W1981690536A5014523351 @default.
• W1981690536 hasAuthorship W1981690536A5023556434 @default.
• W1981690536 hasAuthorship W1981690536A5031355003 @default.
• W1981690536 hasAuthorship W1981690536A5052280892 @default.
• W1981690536 hasAuthorship W1981690536A5063740495 @default.
• W1981690536 hasAuthorship W1981690536A5083798648 @default.
• W1981690536 hasAuthorship W1981690536A5086044070 @default.
• W1981690536 hasConcept C126322002 @default.
• W1981690536 hasConcept C126894567 @default.
• W1981690536 hasConcept C134018914 @default.
• W1981690536 hasConcept C159641895 @default.
• W1981690536 hasConcept C2778033501 @default.
• W1981690536 hasConcept C2779719350 @default.
• W1981690536 hasConcept C2780152017 @default.
• W1981690536 hasConcept C2780306776 @default.
• W1981690536 hasConcept C2909675724 @default.
• W1981690536 hasConcept C2911091166 @default.
• W1981690536 hasConcept C555293320 @default.
• W1981690536 hasConcept C71924100 @default.
• W1981690536 hasConcept C90924648 @default.
• W1981690536 hasConcept C98274493 @default.
• W1981690536 hasConceptScore W1981690536C126322002 @default.
• W1981690536 hasConceptScore W1981690536C126894567 @default.
• W1981690536 hasConceptScore W1981690536C134018914 @default.
• W1981690536 hasConceptScore W1981690536C159641895 @default.
• W1981690536 hasConceptScore W1981690536C2778033501 @default.
• W1981690536 hasConceptScore W1981690536C2779719350 @default.
• W1981690536 hasConceptScore W1981690536C2780152017 @default.
• W1981690536 hasConceptScore W1981690536C2780306776 @default.
• W1981690536 hasConceptScore W1981690536C2909675724 @default.
• W1981690536 hasConceptScore W1981690536C2911091166 @default.
• W1981690536 hasConceptScore W1981690536C555293320 @default.
• W1981690536 hasConceptScore W1981690536C71924100 @default.
• W1981690536 hasConceptScore W1981690536C90924648 @default.
• W1981690536 hasConceptScore W1981690536C98274493 @default.
• W1981690536 hasIssue "6" @default.
• W1981690536 hasLocation W19816905361 @default.
• W1981690536 hasLocation W19816905362 @default.
• W1981690536 hasOpenAccess W1981690536 @default.
• W1981690536 hasPrimaryLocation W19816905361 @default.
• W1981690536 hasRelatedWork W1486584413 @default.
• W1981690536 hasRelatedWork W1544023406 @default.
• W1981690536 hasRelatedWork W1992515321 @default.
• W1981690536 hasRelatedWork W2046899919 @default.
• W1981690536 hasRelatedWork W2071667523 @default.
• W1981690536 hasRelatedWork W2086415357 @default.
• W1981690536 hasRelatedWork W2087086071 @default.
• W1981690536 hasRelatedWork W2159653974 @default.
• W1981690536 hasRelatedWork W393698729 @default.
• W1981690536 hasRelatedWork W4247783454 @default.
• W1981690536 hasVolume "85" @default.
• W1981690536 isParatext "false" @default.
• W1981690536 isRetracted "false" @default.
• W1981690536 magId "1981690536" @default.
• W1981690536 workType "article" @default.